New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancerGuopei Luo, Xianjun Yu, Chao Yang et al.|Pancreatology|2018Cited by 79
The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patientsCheng He, Chen Liu, Guopei Luo et al.|Pancreatology|2016Cited by 65
Epithelial–mesenchymal transition in pancreatic cancer: Is it a clinically significant factor?Jia-Hao Jiang, Xianjun Yu, Liang Liu et al.|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2014Cited by 42
Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repairJin Xu, Xianjun Yu|International Journal of Oncology|2013Cited by 28
A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolismWensheng Liu, Jin Xu|International Journal of Oncology|2017Cited by 26